Zacks Investment Research on MSN
Merck (MRK) exceeds market returns: Some facts to consider
In the latest close session, Merck (MRK) was up +1.31% at $115.68. The stock's change was more than the S&P 500's daily gain of 1.15%. At the same time, the Dow added 1.38%, and the tech-heavy Nasdaq ...
MRK, is presenting new long term data on its GARDASIL 9 and GARDASIL HPV vaccines at a major international HPV congress. The ...
Zacks Investment Research on MSN
Merck (MRK) stock moves -1.18%: What you should know
In the latest close session, Merck (MRK) was down 1.18% at $114.50. This move was narrower than the S&P 500's daily loss of 1.36%. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy ...
Shares of Merck & Co. Inc. MRK slipped 1.18% to $114.50 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.36% to 6,624.70 ...
Today's Research Daily features new research reports on 16 major stocks, including Merck Co., Inc. (MRK), TotalEnergies SE ...
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Value Fund” ...
A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...
Merck MRK is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $16.19 billion ...
Disclosed in the latest SEC filing, a significant insider purchase on January 28, involves Johannes Oosthuizen, President at Merck & Co (NYSE:MRK). What Happened: A Form 4 filing with the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results